You are here

Article info

Article menu
Research letter
Characterisation of an OCS-dependent severe asthma population treated with mepolizumab
Free

Authors

  1. Correspondence to Dr Hector Ortega, GlaxoSmithKline, 5 Moore Drive, PO Box 3317.3A, Research Triangle Park, NC 27709-3398, USA; hector.g.ortega{at}gsk.com
View Full Text

Citation

Prazma CM, Wenzel S, Barnes N, et al
Characterisation of an OCS-dependent severe asthma population treated with mepolizumab
Thorax 2014;69:1141-1142.

Publication history

  • Received April 18, 2014
  • Accepted April 22, 2014
  • First published May 16, 2014.
Online issue publication 
September 01, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions